Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | KDM1A | O60341 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.58 |
| ▸ | CA2 | P00918 | 6/20 | 0.58 |
| ▸ | CA9 | Q16790 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708021 | 0.90 | MAPT (0.68) | EGFRMAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL21708008 | 0.88 | KDM1A (0.67) | EGFRKDM1AMAPTSMN1; SMN2GAA | |
| SCHEMBL10464406 | 0.87 | MAPT (0.65) | EGFRMAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL4789312 | 0.87 | SMN1; SMN2 (0.69) | EGFRMAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL21708010 | 0.86 | GAA (0.64) | EGFRMAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL790315 | 0.86 | MAPT (0.64) | EGFRMAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL525606 | 0.86 | MAOA (0.64) | EGFRMAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL20530863 | 0.84 | SMN1; SMN2 (0.72) | EGFRMAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL525388 | 0.83 | EGFR (0.58) | EGFRMAPTSMN1; SMN2GAAMEN1 | |
| SCHEMBL21708012 | 0.83 | GAA (0.66) | EGFRMAPTSMN1; SMN2GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | disclosed |
| US-7371751-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1694673-B1 | THIAZOLE DERIVATES | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| EP-1694673-A1 | NOVEL THIAZOLE DERIVATES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-30 | — | — | EP | disclosed |
| US-20050153962-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005058887-A1 | NOVEL THIAZOLE DERIVATES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | EGFR 4041/4885KDM1A 1772/4885MAPT 2196/4885 |
| US-20050153962-A1 | Thiazole derivatives | CNR1, CNR2, GPR119 | EGFR 646/4885KDM1A 3213/4885MAPT 3183/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | EGFR 4041/4885KDM1A 1772/4885MAPT 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.